FDA警告治疗骨质疏松的药物存在少见却严重的股骨骨折风险。骨折与受欢迎的治疗骨质疏松的二膦酸盐类药物之间存在联系的说法已有一段时期。这次是FDA首次要求在这类药物标签上加上新的警告。对这类批准用于治疗骨质疏松的药物警告包括默克公司的福善美、罗氏和葛兰素史克公司 FDA warns that there is a rare but significant risk of femoral fractures in medications that treat osteoporosis. Fractures have been linked to the popular bisphosphonates for the treatment of osteoporosis for some time now. This is the first FDA request to add a new warning label on these drugs. Drug warnings approved for the treatment of osteoporosis include Merck’s Fosamax, Roche and GlaxoSmithKline